Meeting Register Page

FFB/Odylia TX – Webinar 4: Funding and Execution of Ocular Drug Development
There are approximately 40 clinical trials aimed at addressing inherited retinal disease and dry Age-Related Macular Degeneration, along with emerging technologies in the preclinical development pipeline. As therapies move from the bench to the bedside, proper funding and management are critical elements in the technology’s journey to the patient population. Financial support comes in many forms, such as venture capital, government programs, or industry to name a few. However, it is paramount that academics align their study designs and goals with these support systems to adequately secure and execute these funds. The other side of the coin is entrepreneurship, management, and oversight. While the technology must address its target disease effectively and safely, ample leadership is imperative to guide and championing the asset as it navigates the path to clinical use.
Here, in Webinar #4 we bring you three experts on venture capital funding, Small Business Innovation Research Funding presented by the National Eye Institute, and entrepreneurship to help demystify some of the critical elements in positioning an emerging therapy into clinical trials and the marketplace. The group will also discuss the emerging retinal disease drug development landscape and give their personal views on the most exciting areas.
Please register today. Let us work together to make this a dynamic event as we encourage a real-time conversation on the topics.
This webinar series is sponsored by Regeneron.

Mar 2, 2021 01:00 PM in Eastern Time (US and Canada)

Meeting logo
Meeting is over, you can not register now. If you have any questions, please contact Meeting host: Leilla Kenney.